Effects of risperidone on glucose metabolism and gut microbiota in healthy adults: an open-label, pilot, randomized controlled trial

Oshima Megumi0 个研究点目标入组 24 人开始时间: 2022年3月22日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•The study includes those who meet all of the following criteria.
•1) Men and women between the ages of 20 and 65
•2) No history of psychiatric or neurological disorders
•3) Fasting blood glucose level less than 140 mg/dL
•4) HOMA-IR (homeostasis model assessment-insulin resistance) 1.6 or higher
•5) Estimated GFR 60 ml/min/1.73 m2 or higher
•6) AST and ALT less than 30 IU/L
•7) No history of arrhythmia or congenital QT prolongation syndrome
•8) No history of active cancer (disease-free for 5 years or less)
•9) Have a bowel movement at least once every 4 days (regardless of whether or not laxatives are used)
•10) The patient's written consent has been obtained after sufficient informed consent for participation in the study

•Illnesses under treatment
•History of hypersensitivity to any of the ingredients of risperidone or paliperidone
•Pregnant or lactating mothers
•Participation in other clinical studies within 3 months prior to the start of administration of the study drug
•Not appropriate as participants
•Working at the same or related departments as the principal investigator

发起方

Oshima Megumi